10x Genomics Reports Significantly Reduced Net Loss and Strong Operating Cash Flow for FY2025, Driven by Patent Settlements Amidst Core Revenue Decline

summarizeSummary

10x Genomics reported a significantly reduced net loss and strong operating cash flow for fiscal year 2025, largely due to patent settlements and cost reductions, despite a decline in core product revenue. The company projects moderate revenue growth for 2026, excluding one-time gains.

check_boxKey Events

• Significant Reduction in Net Loss

  Net loss decreased substantially from $182.6 million in 2024 to $43.5 million in 2025, reflecting improved profitability.

• Strong Operating Cash Flow

  Net cash provided by operating activities surged to $136.1 million in 2025, a significant improvement from $6.7 million in 2024.

• Impact of Patent Litigation Settlements

  The company recognized $49.9 million in gains on settlement and $44.1 million in license and royalty revenue from patent disputes with Vizgen and Bruker, materially boosting financial results.

• Decline in Core Product Revenue

  Products and services revenue decreased by 2% year-over-year, with instrument sales down 39% and single-cell consumables down 2%, partially offset by a 19% increase in spatial consumables.

auto_awesomeAnalysis

10x Genomics' annual report confirms a substantial improvement in its financial health for fiscal year 2025, primarily driven by significant non-recurring gains from patent litigation settlements with Vizgen and Bruker, totaling $49.9 million in gains and $44.1 million in license and royalty revenue. This, combined with a 17% reduction in total operating expenses (including a $26.1 million decrease in R&D and $28.2 million in SG&A), led to a dramatic decrease in net loss from $182.6 million in 2024 to $43.5 million in 2025, and a strong positive operating cash flow of $136.1 million. However, core product and services revenue saw a 2% decline, with instrument sales dropping 39% and single-cell consumables decreasing 2%, partially offset by a 19% increase in spatial consumables. The company also completed the acquisition of Scale Bio, expanding its single-cell portfolio, and undertook a restructuring that resulted in $10.6 million in charges. The outlook for 2026 projects moderate revenue growth (excluding the one-time settlement benefits) and further modest decreases in operating expenses, indicating a continued focus on efficiency and strategic growth despite headwinds in certain product categories.